• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Gabriela Perez Joins Big Health as Chief Commercial Officer

    2/3/22 8:00:00 AM ET
    $LH
    $TDOC
    Medical Specialities
    Health Care
    Medical/Nursing Services
    Health Care
    Get the next $LH alert in real time by email

    After spending two decades successfully scaling multiple healthcare technology companies, Perez joins Big Health to accelerate the commercial coverage and reimbursement for digital therapeutics

    Big Health, a digital therapeutics company dedicated to helping millions back to good mental health, today announced the appointment of Gabriela Perez as Chief Commercial Officer. In her new role, Perez will oversee Big Health's global commercial growth and strategy, including sales, client management, strategic partnerships, and new markets.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220203005297/en/

    Big Health Chief Commercial Officer Gabriela Perez (Photo: Business Wire)

    Big Health Chief Commercial Officer Gabriela Perez (Photo: Business Wire)

    Perez has spent the past two decades building and scaling several technology-enabled healthcare services companies. Most recently, she was Executive Vice President & General Manager at Ovia Health, the largest women & family digital health company in the United States, where she led the company to triple digit year-over-year revenue growth while overseeing more than 2,000 clients and signing 27 new regional and national health plan partnerships. Ovia Health was acquired by Labcorp (NYSE:LH) in August 2021.

    Her entrepreneurial career began as part of the founding team of Best Doctors, a telehealth company that pioneered e-second opinions globally. During her tenure at Best Doctors, Perez held multiple leadership positions across product, marketing, partnerships, and global sales divisions. She was responsible for scaling business units across 45 countries, accounting for hundreds of millions of dollars in revenue. Best Doctors was acquired by Teladoc Health (NYSE:TDOC) in June 2017.

    "Over the past two decades, Gabriela has proven her exceptional ability to drive rapid growth for innovative healthcare companies," said Big Health Co-Founder and CEO Peter Hames. "But what sets Gabriela apart is her humility and mission-driven mentality. This unique combination makes her a perfect fit for Big Health, and we cannot be more excited to welcome her to the team as we continue to accelerate our growth in pursuit of helping millions back to good mental health."

    Big Health is the most scaled digital therapeutics company with the most studied products, including over 10 million covered lives globally, 13 randomized controlled trials evaluating its approach, and more than 28,000 participants across all clinical evidence studies. Sleepio and Daylight¹, Big Health's digital therapeutics for insomnia and anxiety, offer fully automated products that deliver evidence-based mental health care, including cognitive behavioral therapy, without intervention from coaches or clinicians. Through robust clinical evaluation, Big Health's digital therapeutics are proven first-line treatments for mental health care.

    "Over the course of my career in healthcare technology, I have identified three key trends that are paramount to the success of a business: focus on clinical and evidence-based care, purposeful design and engagement, and innovative commercial models," said Perez. "Big Health is leading the digital therapeutics industry in all three areas, and is poised for even faster growth ahead. I cannot be more excited to join Peter and the entire Big Health team to advance our mission of helping millions back to good mental health."

    This key addition follows two momentous announcements for Big Health. In January 2022, Big Health announced a $75 million Series C funding, led by SoftBank Vision Fund 2. The company also announced that it added former Food and Drug Administration (FDA) Deputy Commissioner for Medical and Scientific Affairs Dr. Anand Shah to its Board of Directors to bolster the company's clinical and public policy strategies.

    About Big Health

    Big Health's mission is to help millions back to good mental health by providing safe and effective non-drug alternatives for the most common mental health conditions including insomnia and anxiety. Designed by leading clinical experts, Big Health's digital therapeutics expand access to gold standard care, including behavioral medicine, and are backed by industry-leading research and randomized controlled trials. By seamlessly integrating across the care pathway, from member engagement to billing via pharmacy benefit managers, Big Health simplifies adoption for both payers and patients, providing an inclusive, scalable, and affordable approach without serious side effects. For more information, please visit www.bighealth.com or follow Big Health on LinkedIn and Twitter.

    ¹ In accordance with FDA's Current Enforcement Discretion Policy for Digital Health Devices for Psychiatric Disorders, for patients aged 18 years and older, who are followed by and diagnosed with Insomnia Disorder or Generalized Anxiety Disorder by a medical provider, Sleepio and Daylight can be made available as an adjunct to their usual medical care for Insomnia Disorder or Generalized Anxiety Disorder, respectively. Sleepio and Daylight do not replace the care of a medical provider or the patient's medication. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for these indications.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220203005297/en/

    Get the next $LH alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $LH
    $TDOC

    CompanyDatePrice TargetRatingAnalyst
    Teladoc Health Inc.
    $TDOC
    7/25/2025$10.00Neutral
    Mizuho
    Labcorp Holdings Inc.
    $LH
    7/10/2025$260.00Buy → Hold
    HSBC Securities
    Labcorp Holdings Inc.
    $LH
    4/2/2025$276.00Buy
    Redburn Atlantic
    Labcorp Holdings Inc.
    $LH
    3/4/2025$250.00 → $300.00Neutral → Buy
    Citigroup
    Labcorp Holdings Inc.
    $LH
    1/7/2025$260.00 → $265.00In-line → Outperform
    Evercore ISI
    Labcorp Holdings Inc.
    $LH
    12/10/2024$265.00 → $275.00Buy
    Jefferies
    Teladoc Health Inc.
    $TDOC
    11/15/2024$14.00Buy
    Goldman
    Labcorp Holdings Inc.
    $LH
    10/30/2024Hold → Buy
    HSBC Securities
    More analyst ratings

    $LH
    $TDOC
    SEC Filings

    See more
    • Labcorp Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)

      7/24/25 6:52:21 AM ET
      $LH
      Medical Specialities
      Health Care
    • Teladoc Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - Teladoc Health, Inc. (0001477449) (Filer)

      7/23/25 4:05:35 PM ET
      $TDOC
      Medical/Nursing Services
      Health Care
    • Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)

      7/10/25 6:58:16 AM ET
      $LH
      Medical Specialities
      Health Care

    $LH
    $TDOC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Labcorp Announces 2025 Second Quarter Results

      Raises Full-Year Guidance Financial results from Operations for second quarter 2025 versus second quarter 2024:Revenue: $3.53 billion versus $3.22 billionDiluted EPS: $2.84 versus $2.43Adjusted EPS: $4.35 versus $3.94Raised Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance:Revenue guidance narrowed to 7.5% to 8.6%; midpoint raised by 70 basis pointsAdjusted EPS range narrowed to $16.05 to $16.50; midpoint raised by $0.23Free Cash Flow range of $1.13 billion to $1.28 billion; midpoint raised by $25 millionBroadened our partnerships with hospitals, health systems and regional/local labs and enhanced access to comprehensive testing and laboratory servicesIntroduced several new tests

      7/24/25 6:50:00 AM ET
      $LH
      Medical Specialities
      Health Care
    • Community Health Systems Announces Definitive Agreement to Sell Select Outreach Laboratory Assets to Labcorp

      Agreement aims to provide broader access to testing and laboratory services to communities across the U.S. Community Health Systems, Inc. (Company) (NYSE:CYH) announced today that its subsidiary, CHS/Community Health Systems, Inc. (CHS), has entered into a definitive agreement with Labcorp (NYSE:LH), pursuant to which Labcorp will acquire select assets and assume certain leases of the ambulatory outreach laboratory services of CHS health systems in 13 states, including certain patient service centers and in-office phlebotomy locations, for $195 million cash. When the transaction is complete, CHS patients and providers will benefit from broader access to Labcorp's comprehensive testing a

      7/22/25 4:15:00 PM ET
      $CYH
      $LH
      Hospital/Nursing Management
      Health Care
      Medical Specialities
    • Teladoc Health to Announce Second Quarter 2025 Financial Results

      NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE:TDOC), the global leader in virtual care, announced that it will release second quarter 2025 results on Tuesday, July 29, 2025, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. ET on the same day. Conference Call DetailsThe conference call can be accessed by dialing 1-833-470-1428 for U.S. participants and using the access code # 606269. For international participants, please visit the following link for global dial-in numbers: https://www.netroadshow.com/conferencing/global-numbers?confId=85796. A live audio webcast will also be available online at https://

      7/16/25 4:30:58 PM ET
      $TDOC
      Medical/Nursing Services
      Health Care

    $LH
    $TDOC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Teladoc with a new price target

      Mizuho initiated coverage of Teladoc with a rating of Neutral and set a new price target of $10.00

      7/25/25 9:07:34 AM ET
      $TDOC
      Medical/Nursing Services
      Health Care
    • Labcorp Holdings Inc. downgraded by HSBC Securities with a new price target

      HSBC Securities downgraded Labcorp Holdings Inc. from Buy to Hold and set a new price target of $260.00

      7/10/25 9:03:30 AM ET
      $LH
      Medical Specialities
      Health Care
    • Redburn Atlantic initiated coverage on Labcorp Holdings Inc. with a new price target

      Redburn Atlantic initiated coverage of Labcorp Holdings Inc. with a rating of Buy and set a new price target of $276.00

      4/2/25 8:50:29 AM ET
      $LH
      Medical Specialities
      Health Care

    $LH
    $TDOC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Anderson Kerrii B sold $132,500 worth of shares (500 units at $265.00), decreasing direct ownership by 4% to 12,166 units (SEC Form 4)

      4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

      7/2/25 10:37:22 AM ET
      $LH
      Medical Specialities
      Health Care
    • Director Evans Jason Eric converted options into 1,016 shares, increasing direct ownership by 17% to 7,113 units (SEC Form 4)

      4 - Teladoc Health, Inc. (0001477449) (Issuer)

      6/23/25 4:11:27 PM ET
      $TDOC
      Medical/Nursing Services
      Health Care
    • Director Anderson Kerrii B sold $130,000 worth of shares (500 units at $260.00), decreasing direct ownership by 4% to 12,666 units (SEC Form 4)

      4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

      6/12/25 10:07:20 AM ET
      $LH
      Medical Specialities
      Health Care

    $LH
    $TDOC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mckinley Thomas bought $30,756 worth of shares (4,000 units at $7.69), increasing direct ownership by 11% to 39,077 units (SEC Form 4)

      4 - Teladoc Health, Inc. (0001477449) (Issuer)

      9/13/24 5:14:02 PM ET
      $TDOC
      Medical/Nursing Services
      Health Care
    • Director Smith Mark Douglas bought $28,312 worth of shares (4,000 units at $7.08), increasing direct ownership by 92% to 8,355 units (SEC Form 4)

      4 - Teladoc Health, Inc. (0001477449) (Issuer)

      8/19/24 4:10:41 PM ET
      $TDOC
      Medical/Nursing Services
      Health Care
    • Director Mckinley Thomas bought $81,746 worth of shares (11,000 units at $7.43), increasing direct ownership by 46% to 35,077 units (SEC Form 4)

      4 - Teladoc Health, Inc. (0001477449) (Issuer)

      8/8/24 5:49:44 PM ET
      $TDOC
      Medical/Nursing Services
      Health Care

    $LH
    $TDOC
    Leadership Updates

    Live Leadership Updates

    See more
    • Privia Health Announces Appointment of Lance V. Berberian to its Board of Directors

      ARLINGTON, Va., July 08, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced the appointment of Lance V. Berberian to its Board of Directors, effective July 15, 2025. He has also been named a member of the Audit Committee of the Board. Following the appointment of Mr. Berberian, the Board will comprise 10 directors. "We are excited to welcome Lance to our Board of Directors," said David King, Chairman of the Board, Privia Health Group, Inc. "Lance brings extensive technology strategy and digital transformation experience to the Board, including IT governance, infrastructure management and cybersecurity. We believe his expertise will be invaluable to Privia Health as

      7/8/25 9:00:00 AM ET
      $LH
      $PRVA
      Medical Specialities
      Health Care
      Medical/Nursing Services
    • SOLVD Health Appoints Mike Aicher and Vince Cebula to Board of Directors to Support Next Phase of Growth

      SOLVD Health (SOLVD), a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, has appointed diagnostics pioneer Mike Aicher and strategic advisor Vince Cebula to its Board of Directors. Their combined leadership in molecular diagnostics, healthcare technology, and growth-stage investment will support the company's continued expansion as it scales access to personalized health insights and accelerates development of its precision diagnostics platform. Aicher's expertise in building and scaling diagnostic platforms will be instrumental as SOLVD Health expands its personalized health solutions. He brings more than three decades of executiv

      5/12/25 9:00:00 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp CFO Glenn Eisenberg Announces Plans to Retire

      Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April 2025 to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.

      11/19/24 7:00:00 AM ET
      $BGNE
      $LH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities

    $LH
    $TDOC
    Financials

    Live finance-specific insights

    See more
    • Labcorp Announces 2025 Second Quarter Results

      Raises Full-Year Guidance Financial results from Operations for second quarter 2025 versus second quarter 2024:Revenue: $3.53 billion versus $3.22 billionDiluted EPS: $2.84 versus $2.43Adjusted EPS: $4.35 versus $3.94Raised Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance:Revenue guidance narrowed to 7.5% to 8.6%; midpoint raised by 70 basis pointsAdjusted EPS range narrowed to $16.05 to $16.50; midpoint raised by $0.23Free Cash Flow range of $1.13 billion to $1.28 billion; midpoint raised by $25 millionBroadened our partnerships with hospitals, health systems and regional/local labs and enhanced access to comprehensive testing and laboratory servicesIntroduced several new tests

      7/24/25 6:50:00 AM ET
      $LH
      Medical Specialities
      Health Care
    • Teladoc Health to Announce Second Quarter 2025 Financial Results

      NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE:TDOC), the global leader in virtual care, announced that it will release second quarter 2025 results on Tuesday, July 29, 2025, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. ET on the same day. Conference Call DetailsThe conference call can be accessed by dialing 1-833-470-1428 for U.S. participants and using the access code # 606269. For international participants, please visit the following link for global dial-in numbers: https://www.netroadshow.com/conferencing/global-numbers?confId=85796. A live audio webcast will also be available online at https://

      7/16/25 4:30:58 PM ET
      $TDOC
      Medical/Nursing Services
      Health Care
    • Labcorp Declares Quarterly Dividend

      BURLINGTON, N.C., July 10, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on September 11, 2025, to stockholders of record as of the close of business on August 28, 2025. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and

      7/10/25 6:50:00 AM ET
      $LH
      Medical Specialities
      Health Care

    $LH
    $TDOC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Teladoc Health Inc.

      SC 13G - Teladoc Health, Inc. (0001477449) (Subject)

      9/5/24 4:36:22 PM ET
      $TDOC
      Medical/Nursing Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Teladoc Health Inc.

      SC 13G/A - Teladoc Health, Inc. (0001477449) (Subject)

      7/8/24 4:32:41 PM ET
      $TDOC
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G/A filed by Teladoc Health Inc. (Amendment)

      SC 13G/A - Teladoc Health, Inc. (0001477449) (Subject)

      2/13/24 5:16:08 PM ET
      $TDOC
      Medical/Nursing Services
      Health Care